Entrectinib-Induced Heart Failure in a Patient With Metastatic Lung Adenocarcinoma: A Case Report

Entrectinib is a recently approved multikinase inhibitor to treat advanced c-ros oncogene1 (ROS1) positive non-small cell lung cancer (NSCLC). Although molecular targeted therapy is generally well tolerated, cardiovascular adverse events have been described in recent years. We report a case of NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales: Otsu, Yukiko, Kata, Yuki, Takayasu, Hirokazu, Inoue, Satoshi, Kaneko, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808486/
https://www.ncbi.nlm.nih.gov/pubmed/36605067
http://dx.doi.org/10.7759/cureus.32174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808486/
https://www.ncbi.nlm.nih.gov/pubmed/36605067
http://dx.doi.org/10.7759/cureus.32174

Ejemplares similares